BAY 85-8501

inhibits neutrophil elastase; structure in first source

Also Known As:

4-(4-cyano-2-(methylsulfonyl)phenyl)-3,6-dimethyl-2-oxo-1-(3-(trifluoromethyl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carbonitrile

Networked: 2 relevant articles (1 outcomes, 1 trials/studies)

1.	Bandel, Tiemo-Joerg: 1 article (01/2019)
2.	Kirsten, Anne: 1 article (01/2019)
3.	Nagelschmitz, Johannes: 1 article (01/2019)
4.	Pedersen, Frauke: 1 article (01/2019)
5.	Rabe, Klaus F: 1 article (01/2019)
6.	Schwers, Stephan: 1 article (01/2019)
7.	Watz, Henrik: 1 article (01/2019)
8.	van der Mey, Dorina: 1 article (01/2019)
9.	Allerheiligen, Swen: 1 article (07/2015)
10.	Anlauf, Sonja: 1 article (07/2015)

1.	Cystic Fibrosis (Mucoviscidosis) 01/01/2019 - "Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial."
2.	Bronchiectasis 01/01/2019 - "Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial."
3.	Lung Diseases (Lung Disease) 07/01/2015 - "BAY 85-8501 is currently being tested in clinical studies for the treatment of pulmonary diseases."

1.	Secretory Proteinase Inhibitory Proteins